Study Details

General Information

Assurex MDD ARX1006

A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by and Open-Label 12-Week follow-up Period of Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering from Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - and Inadequate Response to at Least One Psychotropic Medication included in Gene Sight Psychotropic.

ProtocolARX1006
IdentifierSite No: 223 Project Code: 1003452
UIDfc8f8eeb-9fd8-4262-be96-762c3a30448b
StatusDone - Archived
PhaseIV
CategoryMajor Depressive Disorder / Adult
Launch Year2015
NCT Number-
Created2015-05-15 09:56
Last Updated2015-05-15 09:56

Description

No description provided.

Comment

No comment.

Target Dates

NameDateRequired
Enrollment Closed2016-01-20No
Enrollment Open2015-07-29No
First Patient First VisitNo
Site Initiation Mtg.2015-07-22No
PI Meeting StartNo
PI Meeting EndNo
PI Meeting ArrivalNo
PI Meeting DepartureNo
Closeout Date2016-04-29No
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalMartinez, GilbertGJMartinezNo
Recruiter-No
CoordinatorBarnett, OmarOBarnettNo
RegulatoryAguirre, SandraSAguirreNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorAssurex Healthcare, Inc
DivisionAssure RX
TeamAssurex
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB Ref
CROInc Research, LLC
CRO Ref
Correspondence0

Opportunity

Probability0
Comment
Status ColorGainsboro
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?